Department of Clinical and Experimental Medicine, Regional Reference Centre for Coagulation Disorders, "Federico II" University, 80131 Naples, Italy.
World J Gastroenterol. 2012 Nov 7;18(41):5839-47. doi: 10.3748/wjg.v18.i41.5839.
Non-alcoholic fatty liver disease (NAFLD) has been recognized as a major health burden. It is the most important cause of chronic liver disease and a major independent cardiovascular risk factor. Lacking a definite treatment for NAFLD, a specific diet and an increase in physical activity represent the most commonly used therapeutic approaches. In this review, major literature data about the use of omega-3 polyunsaturated fatty acids (n-3 PUFAs) as a potential treatment of NAFLD have been described. n-3 PUFAs, besides having a beneficial impact on most of the cardio-metabolic risk factors (hypertension, hyperlipidemia, endothelial dysfunction and atherosclerosis) by regulating gene transcription factors [i.e., peroxisome proliferator-activated receptor (PPAR) α, PPARγ, sterol regulatory element-binding protein-1, carbohydrate responsive element-binding protein], impacts both lipid metabolism and on insulin sensitivity. In addition to an enhancement of hepatic beta oxidation and a decrease of the endogenous lipid production, n-3 PUFAs are able to determine a significant reduction of the expression of pro-inflammatory molecules (tumor necrosis factor-α and interleukin-6) and of oxygen reactive species. Further strengthening the results of the in vitro studies, both animal models and human intervention trials, showed a beneficial effect of n-3 PUFAs on the severity of NAFLD as expressed by laboratory parameters and imaging measurements. Despite available results provided encouraging data about the efficacy of n-3 PUFAs as a treatment of NAFLD in humans, well-designed randomized controlled trials of adequate size and duration, with histological endpoints, are needed to assess the long-term safety and efficacy of PUFA, as well as other therapies, for the treatment of NAFLD and non-alcoholic steatohepatitis patients. It is worthwhile to consider that n-3 PUFAs cannot be synthesized by the human body and must be derived from exogenous sources (fish oil, flaxseeds, olive oil) which are typical foods of the Mediterranean diet, known for its beneficial effects in preventing obesity, diabetes and, in turn, cardiovascular events. According to these data, it is important to consider that most of the beneficial effects of n-3 PUFAs can also be obtained by an equilibrate nutrition program.
非酒精性脂肪性肝病(NAFLD)已被认为是一个主要的健康负担。它是慢性肝病的最重要原因,也是心血管疾病的一个主要独立危险因素。由于缺乏对 NAFLD 的明确治疗方法,特定的饮食和增加身体活动是最常用的治疗方法。在这篇综述中,描述了关于使用ω-3 多不饱和脂肪酸(n-3 PUFAs)作为 NAFLD 潜在治疗方法的主要文献数据。n-3 PUFAs 通过调节基因转录因子(即过氧化物酶体增殖物激活受体(PPAR)α、PPARγ、固醇调节元件结合蛋白-1、碳水化合物反应元件结合蛋白),对大多数心血管代谢危险因素(高血压、高血脂、内皮功能障碍和动脉粥样硬化)产生有益影响,同时影响脂质代谢和胰岛素敏感性。除了增强肝β氧化和减少内源性脂质产生外,n-3 PUFAs 还能够显著降低促炎分子(肿瘤坏死因子-α和白细胞介素-6)和氧反应性物质的表达。进一步加强体外研究的结果,动物模型和人体干预试验都表明,n-3 PUFAs 对 NAFLD 的严重程度有有益的影响,这可以通过实验室参数和影像学测量来表达。尽管现有的结果提供了关于 n-3 PUFAs 作为人类 NAFLD 治疗的有效性的令人鼓舞的数据,但需要设计适当大小和持续时间的、具有组织学终点的、随机对照试验,以评估 PUFA 以及其他治疗方法治疗 NAFLD 和非酒精性脂肪性肝炎患者的长期安全性和有效性。值得考虑的是,人体不能合成 n-3 PUFAs,必须从外源性来源(鱼油、亚麻籽、橄榄油)中获得,这些都是地中海饮食的典型食物,因其在预防肥胖、糖尿病和进而预防心血管事件方面的有益作用而闻名。根据这些数据,重要的是要考虑到 n-3 PUFAs 的大部分有益作用也可以通过均衡的营养计划来获得。